

Trentadil : at last- a real advance in the management of respiratory and cardiac insufficiency.

Contributors

Armour Pharmaceutical Company Limited

Publication/Creation

Eastbourne, Sussex : Armour Pharmaceutical Company Ltd., [approximately 1962]

Persistent URL

<https://wellcomecollection.org/works/jxa7etw7>


License and attribution

Conditions of use: it is possible this item is protected by copyright and/or related rights. You are free to use this item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).



Wellcome Collection
183 Euston Road
London NW1 2BE UK
T +44 (0)20 7611 8722
E library@wellcomecollection.org
<https://wellcomecollection.org>

At last -
a real advance
in the management
of respiratory
and cardiac
insufficiency



Trentadil

Trentadil

bamifylline hydrochloride

a simplified and
improved therapy for
asthma, bronchitis
and coronary
insufficiency

because Trentadil

increases respiratory efficiency
improves coronary blood flow
rapidly effective within 15-20 minutes
does not induce **CNS** stimulation
causes no gastro-intestinal irritation

ELIMINATES THE NEED FOR COMBINATION THERAPY

Trentadil

bronchiole and
coronary dilator
specific
respiratory
stimulant



Theophylline and other xanthine derivatives have long been used to dilate bronchioles and coronary arteries but none has so far proved entirely satisfactory as a single therapeutic agent:—

theophylline, being only slightly soluble in water, is poorly absorbed;

aminophylline is water soluble because it is associated with a hydrophylic group, but this does not increase its pharmacological activity—both theophylline and aminophylline often cause severe gastro-intestinal irritation; stimulation of the respiratory centre, whether by xanthines or ephedrine, is accompanied by general excitation—hence the classic theophylline/ephedrine/barbiturate combination in the treatment of asthma and bronchitis.

Trentadil is a xanthine derivative with a hydrophylic group as part of the molecule which not only makes it water soluble but increases its pharmacological activity so that the addition of ephedrine is no longer necessary.

Trentadil is a more active analeptic than aminophylline **but has no excitatory effect** so that patients no longer require concomitant barbiturate therapy.

Trentadil does not cause gastric or intestinal upset.

Trentadil

bamifylline hydrochloride

actions

stimulation of the respiratory centre
bronchodilatation
coronary dilatation and peripheral vasodilatation
biliary and intestinal spasmolysis
mild diuresis

main indications

asthma, cardiac insufficiencies,
bronchitis, bronchial spasm

presentation

sugar coated tablets containing
300 mg bamifylline hydrochloride in bottle of 100.
Basic N.H.S. cost of 100 tablets 25s. plus P.T.

dosage

Initially, or in severe cases,
two tablets three times a day
For maintenance: one tablet three times a day
For the time being
Trentadil is limited to hospitals only.

reference

Georges, A., Page, J., Duvernay, G., Therapie 1962, XVII, 211-225

Manufactured under licence from A. Christiaens, S.A. Brussels.

Further information is available on request



ARMOUR PHARMACEUTICAL COMPANY LIMITED
EASTBOURNE SUSSEX

B2321AR

TR/L 46/4